Abstract: Peptides and pharmaceutically acceptable salts thereof and peptide conjugates and pharmaceutically acceptable salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:1) for use in treating a subject suffering from or at risk of an inflammatory disease or disorder, schizophrenia or psychosis, a neurodegenerative disease such as Parkinson's disease. Alzheimer's disease, or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease. Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, or nicotine use disorder, tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE) (e.g.

Abstract: Peptides, salts thereof, peptide conjugates, and salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID) NO: 34).

Abstract: Provided is a cognitive function-improving composition. Specifically, provided is a cognitive function-improving composition comprising at least one selected from the group consisting of a thermolysin digest of ovalbumin, a peptide comprising amino acid sequence LP, and a peptide comprising amino acid sequence LE.

Abstract: Provided is a composition for improving leptin resistance, a composition for enhancing leptin sensitivity, a composition for suppressing food intake, or a composition for anti-obesity. Specifically, provided is a composition for improving leptin resistance or enhancing leptin sensitivity, comprising a peptide comprising the amino acid sequence YAB as an active ingredient, wherein A is an amino acid residue having a basic side chain, and B is an amino acid residue having a nonpolar side chain or an amino acid residue having an acidic side chain.

Abstract: The present invention addresses the problem of providing a novel peptide which can treat, prevent or ameliorate anorexia. The present invention provides a peptide described in any one of the following items (1) to (3). (1) A peptide consisting of 4 to 9 inclusive contiguous amino acid residues in the amino acid sequence represented by SEQ ID NO: 1; (2) a peptide consisting of 4 to 12 inclusive contiguous amino acid residues in the amino acid sequence represented by SEQ ID NO: 2; and (3) a peptide consisting of an amino acid sequence having 90% or higher identity to the amino acid sequence represented by SEQ ID NO: 2.

Abstract: The present invention provides peptides, salts thereof, peptide conjugates, and salts thereof having an anxiolytic-like effect, for example a peptide comprising any amino acid sequence selected from (i) an amino acid sequence SYLPPLTT (SEQ ID NO: 1), (ii) an amino acid sequence YHIEPV (SEQ ID NO: 2), (iii) an amino acid sequence YLLVK (SEQ ID NO: 3), (iv) an amino acid sequence SYLPPLT (SEQ ID NO: 4), (v) an amino acid sequence FLLVK (SEQ ID) NO. 5), and (vi) an amino acid sequence WLLVK (SEQ ID NO: 6).

Abstract: A peptide which can be easily taken on a daily basis and which has few side effects and has various actions and a composition containing the peptide as an active ingredient are provided. A peptide having the amino acid sequence of (a) or (b) below is provided. (a) The amino acid sequence of SEQ ID NO: 1 (Asn-Leu-Pro-Pro-Leu-Thr). (b) An amino acid sequence in which one or several amino acids are substituted, deleted or added in the amino acid sequence of SEQ ID NO: 1. Moreover, a composition containing the peptide as an active ingredient is also provided.

Abstract: This invention provides a peptide consisting of (i) the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTQAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).

Abstract: The present invention addresses the problem of providing a novel peptide that can be used to treat, prevent, or ameliorate mood disorders. The present invention provides a peptide that has an amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and is 3 to 5 (inclusive) amino acids long. The peptide may consist of an amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

Abstract: An object of the present invention is to provide a peptide having an excellent effect in terms of preventing deterioration in cognitive function and improving cognitive function, and provide its usage. The present invention uses the tripeptide represented by Tyr-Leu-Gly as an active ingredient of a composition for improving cognitive function or a composition for promoting brain-derived neurotrophic factor expression in the hippocampus. These compositions include a food composition, a food additive composition, and a pharmaceutical composition.

Abstract: Peptides, salts thereof, peptide conjugates, and salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:34).

Abstract: The present invention addresses the problem of providing a novel peptide capable of treating, preventing, or ameliorating a mood disorder. The present invention provides a peptide having an amino acid sequence represented by SEQ ID NO: 1 and having an amino acid length of 6 to 20.

Abstract: An object of the present invention is to provide a peptide having an excellent effect in terms of preventing deterioration in cognitive function and improving cognitive function, and provide its usage. The present invention uses the tripeptide represented by Tyr-Leu-Gly as an active ingredient of a composition for improving cognitive function or a composition for promoting brain-derived neurotrophic factor expression in the hippocampus. These compositions include a food composition, a food additive composition, and a pharmaceutical composition.

Abstract: Provided is a novel peptide having ACE inhibitory activity. Specifically, provided is a tripeptide consisting of Leu-Arg-Ala.

Abstract: The present invention provides peptides, salts thereof, peptide conjugates, and salts thereof having an anxiolytic-like effect, for example a peptide comprising any amino acid sequence selected from (i) an amino acid sequence SYLPPLTT (SEQ ID NO: 1), (ii) an amino acid sequence YHIEPV (SEQ ID NO: 2), (iii) an amino acid sequence YLLVK (SEQ ID NO: 3), (iv) an amino acid sequence SYLPPLT (SEQ ID NO: 4), (v) an amino acid sequence FLLVK (SEQ ID NO: 5), and (vi) an amino acid sequence WLLVK (SEQ ID NO: 6).

Abstract: Peptides, salts thereof, peptide conjugates, and salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:34).

Abstract: Provided is a novel peptide having ACE inhibitory activity. Specifically, provided is a tripeptide consisting of Leu-Arg-Ala.

Abstract: This invention provides a peptide consisting of (i) the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTQAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).

Abstract: This invention provides a peptide consisting of (i) the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTQAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).

Abstract: An agent for secreting ghrelin, comprising ornithine or a salt thereof as an active ingredient, an agent for enhancing eating activity, comprising ornithine or a salt thereof as an active ingredient, and an agent for enhancing gastrointestinal activity, comprising ornithine or a salt thereof as an active ingredient.